Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors.

ABSTRACT:

Background

Headache is one of the most frequently reported symptoms in post-COVID patients. The clinical phenotype of COVID-19 headache combines phenotypic features of both tension-type headache (TTH) and migraine. We aimed to assess the effectiveness, side effects and predictors of amitriptyline (AMT) response in a real-world study setting.

Methods

We performed an observational multicentric study with a retrospective cohort. All consecutive patients with confirmed COVID-19 infection who received AMT for post-COVID headache from March 2020 to May 2021 were included. Response was evaluated by the reduction in the number of headache days per month (HDM) between weeks 8 and 12, compared with the baseline. We explored which variables were associated with a higher probability of

SUBMITTER: Gonzalez-Martinez A 

PROVIDER: S-EPMC9553757 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature